Mutaflor (Escherichia Coli Strain Nissle 1917)

The strain colonises the intestinal lumen, where it competes with harmful bacteria, reinforces tight‑junction proteins, and stimulates anti‑inflammatory pathways. It also produces antimicrobial peptides and modulates immune cell activity, which together improve the mucosal barrier and promote a healthier microbial ecosystem.

The prescribed dose of Mutaflor is set by the treating clinician based on the patient’s condition, age, and overall health. Each capsule contains a fixed 2.5 × 10⁹ colony‑forming units, and the prescriber decides the frequency and duration of therapy.

Safety data for Mutaflor in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against uncertain risks before prescribing it to pregnant or nursing individuals.

To order Mutaflor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mutaflor contains a single, well‑studied strain—Escherichia coli Nissle 1917—whereas many other probiotics combine multiple species. Clinical evidence supports its specific role in ulcerative colitis maintenance, a benefit not consistently demonstrated with generic multi‑strain products. Its regulatory status as a prescription‑only medication also distinguishes it from over‑the‑counter supplements.

Mutaflor capsules should be stored at ambient temperature below 25 °C. Keep them in the original blister pack, protect from moisture and direct heat, and avoid exposure to excessive humidity to maintain bacterial viability.

Mutaflor is taken orally, usually with water. The capsule is swallowed whole and should be used as directed by the prescribing clinician, who will determine the appropriate dosing schedule for the individual patient.

Serious but rare risks include allergic reactions such as rash or swelling, and systemic infections like sepsis or bacteremia, particularly in patients with severe immunosuppression. Prompt medical attention is required if signs of infection or hypersensitivity develop.

Mutaflor is contraindicated in individuals with known hypersensitivity to Escherichia coli Nissle 1917 or any capsule excipients. It should be used with caution, or avoided, in patients with severe immunodeficiency, uncontrolled critical illness, or those receiving intensive immunosuppressive therapy.